A new startup is taking the sequencing market by storm with an ambitious plan to offer affordable and fast, high-throughput sequencing to the masses.
Illumina will use its Illumina Science platform, which it acquired in July, to make cheap, low-cost and high-quality sequencing for the vast majority of genome-wide data sets.
And while Illumina doesn’t offer a fully automated approach to data processing, it’s offering an “artificial intelligence” platform that allows it to perform complex, high throughput analyses.
The Illumina Scientific platform is already being used to make an entire suite of tools to identify genetic variants, which Illumina says can lead to discoveries in the future.
Illumine says the technology it’s building for sequencing is comparable to those available in a wide range of biological systems, from plants to animals and even humans.
It has already produced hundreds of thousands of sequenced samples, and Illumina is building out the capabilities to process the vast amount of data currently generated in the field.
For now, though, Illumina has focused on its ability to make inexpensive and high quality sequencing of large genomes.
And the company has raised $1.6 billion to date, with the money from several private investors including Goldman Sachs, Sequoia Capital, and Andreessen Horowitz.
In addition to providing cheap and high throughput sequencing to large data sets, the Illumina platform is designed to make it easy for the public to participate in the analysis of large genome data sets and to make a living from the data.
That means it can serve as a source for commercial data and for companies to sell their services to the public.
It’s also designed to offer a way to scale the data set to meet the needs of different data sets without needing to invest in expensive machines.
The first step is to use the Illumine Science platform to sequence the human genome.
Then, Illumine will take the sequencing data and use it to build a set of tools that can automatically process the data to produce an analysis of the genome.
That analysis is used to determine what genes or regions of the genomes are most relevant for a disease.
The tools are then built on top of that data and integrated into a custom analysis tool that will make recommendations on the most likely gene or region of interest.
As an example, the company is already creating a tool called the Illuminia Bioinformatics Algorithm to generate a list of potential human-caused diseases.
It will eventually provide recommendations on whether to add a gene to the list.
For a company that has been building a suite of high-end sequencing platforms, Illumin has a unique approach to sequencing data.
The company has developed its own DNA sequencing technology called a “gene-sequencing platform.”
This means that a company is essentially writing software that uses a large amount of genetic material to read the DNA of an individual.
The DNA will be sequenced and then the results are analyzed to identify which genes or proteins are involved in the disease.
That data can be stored in a database, and a company can then build a custom tool to analyze that data.
But Illumina also uses the technology to build out tools that allow the public and scientists to analyze the genomes of other species.
One example is the Illumination Science platform.
This is the platform that will allow scientists to compare the genomes and compare their differences with the genomes from other species to create predictions about how they may be related.
The idea is that if you’re going to work with different species, it helps to have a tool that can compare the DNA sequence from each species to see how similar they are.
The platform also allows scientists to visualize their results in a way that is easy to visualize and understand.
The technology is also used to create the Bioinformatica, an annotation tool that is designed specifically for identifying the genetic variations that are important for disease.
A company called BIO, which is part of Illumina’s scientific arm, is also building out tools to help scientists make personalized recommendations on which genes to target for a particular treatment.
In a few years, the platform could be used to help the public do personalized research on disease.
While the platform has the potential to make some genetic sequencing affordable, the cost of the sequencing will have to be very high to compete with the costs of machines that are already available.
But the Illumino Science platform will have the potential of making some genetic data affordable, too.
In the future, when the sequencing is done by the company’s proprietary technology, there will be a single platform that does it all.
Illumino says that it’s developing the technology so that it can be used in a number of different environments.
That includes the environment of hospitals, where patients are treated in the same way they would be in a normal hospital.
The same technology can also be used for medical imaging, which uses the same sequencing technique.
And of course, if the sequencing happens in the lab, the data will be available to other labs around the world.
So the Illumin